Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MOMETASONE FUROATE

All products: general benefit

Other products in the same Health Canada class (R03BA) — coverage varies; not interchangeable

  • Beclomethasone dipropionate (Qvar): general benefit
  • Budesonide (Pulmicort Nebuamp): general benefit, Limited Use 260, 261, 262, 263, 264
  • Ciclesonide (Alvesco): general benefit
  • Fluticasone furoate (Arnuity Ellipta): general benefit
  • Fluticasone (Flovent HFA): general benefit

Asmanex Twisthaler · DIN 02243596 · 400mcg/Metered Dose · dry-powder inhaler, 30 doses

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Asmanex Twisthaler · DIN 02243596 Manufacturer: Organon Canada Inc.; listing date 2012-12-21 Health Canada: Marketed since 2022-01-04 · brand ASMANEX TWISTHALER · ATC R03BA07 MOMETASONE · form Powder · route Inhalation · ingredients MOMETASONE FUROATE 400 MCG/ACT · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Asmanex Twisthaler: Formulary list price $42.4320/unit (unit not stated in source; not the patient's cost)

Ministry pays: $42.4320 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67514 · Verify on the e-Formulary ↗ (DIN 02243596)

Source record
DIN 02243596: Asmanex Twisthaler Raw flags: sec3=Y Item: 680400109; group id 717; item number 1771; lccId None; manufacturer id OCI Source form: Pd Inh-30 Dose Pk; strength: 400mcg/Metered Dose Recorded listing: General benefit Source prices (unrounded): $42.4320; ministry $42.4320 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243596 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67514 Therapeutic Notes (formulary) NOTES: The general direction of the therapy of asthma has been toward the use of anti-inflammatory agents, especially inhaled steroids, which are not associated with systemic side effects to the same degree as oral steroids. The proper technique of inhalation or use of a spacer is very important to the efficacy of these agents. Physicians and pharmacists should ensure that patients are appropriately instructed in the use of these devices.
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications ELOCOM® (mometasone furoate) Cream, Ointment and Lotion 0.1%: • are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses such as psoriasis and atopic dermatitis. The lotion formulation may be applied to scalp lesions. • can be used for a maximum of 3 weeks duration on the body and of 5 days duration on the face, scalp, axillae and scrotum. 1.1. Pediatrics Pediatrics (<18 years of age): Safety and efficacy of ELOCOM have not been established in pediatric patients (see 7. Warnings and Precautions, 7.1. Special Populations, 7.1.3. Pediatrics). 1.2. Geriatrics Geriatrics (≥ 65 years of age): No overall differences in safety and effectiveness were observed between subjects greater than 65 years of age and younger subjects receiving ELOCOM Cream or Ointment. Clinical trials of ELOCOM Lotion did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. Geriatric patients may be more susceptible to the potential effects of systemic absorption. Decreased hepatic or renal function in the elderly may delay elimination (see … https://pdf.hres.ca/dpd_pm/00081816.PDF PM date: 2025-09-19 Source product: ELOCOM; DIN 00851736; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.